IQVNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 31
IQVIA HOLDINGS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$265.88−1.02 (-0.38%)
Close on Oct 19, 2026
- Market cap
- $44.48B
- P/E (TTM)
- 33.0
- Dividend yield
- –
IQVIA HOLDINGS INC. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Solutions | $9.57B | $9.36B | $8.90B | $9.01B | $8.91B | $8.69B | $8.53B | $8.56B | $8.52B | $8.46B | $8.40B | $8.30B | 56.3% | +7.4% |
| Technology And Analytics Solutions | – | – | $6.63B | $6.46B | $6.39B | $6.25B | $6.16B | $6.03B | $5.91B | $5.87B | $5.86B | $5.83B | – | – |
| Contract Sales & Medical Solutions | – | – | $788.00M | $755.00M | $726.00M | $710.00M | $718.00M | $727.00M | $730.00M | $734.00M | $727.00M | $723.00M | – | – |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $8.03B | $7.92B | $7.75B | $7.53B | $7.43B | $7.36B | $7.36B | $7.58B | $7.60B | $7.55B | $7.55B | $7.34B | 47.3% | +8.0% |
| Europe and Africa | $5.48B | $5.32B | $5.19B | $5.06B | $5.05B | $4.99B | $4.92B | $4.78B | $4.58B | $4.52B | $4.46B | $4.37B | 32.3% | +8.6% |
| Asia-Pacific | $3.47B | $3.39B | $3.38B | $3.32B | $3.22B | $3.15B | $3.13B | $2.96B | $2.98B | $2.99B | $2.97B | $3.14B | 20.4% | +8.0% |
From the segment and revenue-disaggregation notes of Iqvia's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.